NCT05767645招募中不适用
Mistral Percutaneous Tricuspid Valve Durable Repair Pivotal Study
Mitralix1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2021年6月21日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 75
- 试验地点
- 1
- 主要终点
- • Safety
研究概览
简要总结
The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).
The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
详细描述
The main objectives of this study are to evaluate safety and effectiveness of the Mistral implant for the percutaneous treatment of patients with symptomatic moderate or greater tricuspid regurgitation (TR) who are at high risk for tricuspid valve surgery.
Primary endpoints:
- Safety: Incidence of Major Device Related Adverse Events (MDRAE). [Time frame: 6 months].
- Efficacy: Echocardiographic improvement in TR severity of at least 1 grade [Time Frame: 30 days].
Secondary endpoints:
Safety:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is able and willing to give informed consent, follow protocol procedures, and comply with follow-up visit requirements
- •Subject is ≥ 18 years of age or legal age in host country
- •Minimum of moderate functional or degenerative tricuspid regurgitation:
- •Subjects with moderate TR: Only NYHA (New York Heart Association) Class III or IV maybe considered for inclusion.
- •Subjects with severe or greater TR: NYHA (New York Heart Association) Class II, III, or IV may be considered for inclusion
- •Subject has left ventricular ejection fraction (LVEF) >20 %
- •The subject is at high risk of mortality with tricuspid valve surgery as determined by the cardiac surgeon and an interventional cardiologist at the site (center heart team).
- •Femoral or Jugular access of the Steerable Catheter with MDS (Mistral Delivery System) is determined to be feasible.
- •Subject must agree not to start participating in any other clinical trial for a period of 6 months following the index procedure.
- •As determined by the center heart team, the Mistral is the suitable treatment option.
排除标准
- •Tricuspid Stenosis >mild
- •Tricuspid Sub valvular calcification or calcification of the chordae.
- •Subjects with Mitral valve severe stenosis and/or severe regurgitation.
- •Previous tricuspid valve repair or replacement that would interfere with placement of Mistral
- •Subjects with severe, uncontrolled hypertension.
- •Subjects, which need to undergo an emergency surgery.
- •Subject is currently participating in another clinical trial that has not yet completed its primary endpoints.
- •Subject has a history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within the past 30 days.
- •Subject has a history of a myocardial infarction (MI) in the past 30 days.
- •Subject has had a percutaneous coronary intervention (PCI), within the last 30 days before procedure.
- •Subject with active endocarditis.
- •Subject has echocardiographic evidence of intra-cardiac mass, thrombus, vegetation or soft-mobile deposits.
- •Subject has hemodynamic instability requiring inotropic or mechanical support.
- •Subject has a known hypersensitivity or contraindication to anticoagulant and antiplatelet medication.
- •Subject is on chronic dialysis.
- •Bleeding disorders or hypercoagulable state.
- •In the judgment of the Investigator, co-morbid condition(s) that could limit the subject's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study.
- •Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding.
- •Subject has a known allergy to Nitinol alloys, 316L\304 stainless steel.
- •Pregnant or lactating women.
- •Patients being dependent upon the sponsor or upon the investigator or upon the investigational site.
- •According to investigator on site the patient is suffering from a severe end stage disease (e.g. malignancy, severe pulmonary disease, liver disease, renal failure).
- •Contraindication for TEE (transesophageal echocardiography) including trans-gastric views.
- •Life expectancy of less than 1 year
结局指标
主要结局
• Safety
时间窗: 6 months
Incidence of Major Device Related Adverse Events (MDRAE).
次要结局
- Safety - Incidence of device or procedure related serious adverse events(30 days)
- Effectiveness TR(1, 6, 12, and 24 months over baseline)
- Safety - Incidence of Major Device Related Adverse Events(1, 6, 12, and 24 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
MATTERS II - Mistral Percutaneous Tricuspid Valve Repair FIM StudyTricuspid Valve RegurgitationNCT04073979Mitralix9
已完成
不适用
MATTERS Study - Mistral Percutaneous Tricuspid Valve Repair FIM StudyTricuspid Valve RegurgitationNCT04071652Mitralix17
已完成
不适用
MERIT Study - Mistral Percutaneous Mitral Valve Repair FIM StudyMitral Valve RegurgitationNCT02948231Mitralix4
招募中
不适用
European Registry of Transcatheter Repair for Tricuspid RegurgitationValvular Heart DiseaseHeart FailureTricuspid RegurgitationNCT06307262LMU Klinikum3,000
终止
不适用
REPAIR - transcatheteR rEPair of mitrAl Insufficiency With caRdioband SystemMitral Valve InsufficiencyCardiac Valve AnnuloplastyMitral Valve AnnuloplastyCardiovascular DiseasesHeart DiseasesHeart Valve DiseasesMitral RegurgitationNCT02703311Edwards Lifesciences11